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Established Facts 
• Conventional noninvasive prenatal test (NIPT) requires a cell-free fetal DNA fraction above 3–4% in 
order to ensure a reliable NIPT result.
• Obesity is associated with a decrease in the fetal fraction and a higher rate of failed NIPT results.
Novel Insights
• Increasing BMI tends to decrease the quantity of fetal cells available for cell-based NIPT, but not sig-
nificantly.
• Cell-based NIPT will unlikely be affected by BMI as every sample renders fetal cells.
DOI: 10.1159/000492028
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Abstract
We present the first study that investigates the effect of ma-
ternal body mass index (BMI) on the quantity of circulating 
fetal cells available to use in cell-based noninvasive prenatal 
test (cbNIPT). cbNIPT has been proposed as a superior alter-
native to noninvasive prenatal test from cell-free fetal DNA. 
Kølvraa et al. [Prenat Diagn. 2016 Dec; 36(12): 1127–34] es-
tablished that cbNIPT can be performed on as few as one 
fetal cell, and Vestergaard et al. [Prenat Diagn. 2017 Nov; 
37(11): 1120–4] demonstrated that these fetal trophoblast 
cells could be used successfully in cbNIPT to detect chromo-
somal and sub-chromosomal abnormalities. This study on 91 
pregnant women with high-risk pregnancies suggests that 
cbNIPT should not be hampered by an increased BMI be-
cause every pregnancy, irrespective of the BMI, has rendered 
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fetal cells for downstream genetic analysis. The mean num-
ber of fetal cells per sample was 12.6, with a range of 1–43 
cells in one sample. ANOVA showed that increasing mater-
nal BMI tends to decrease the number of fetal cells, but not 
significantly. © 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Noninvasive prenatal testing (NIPT) based on cell-free 
fetal DNA (cffDNA) circulating in maternal plasma pro-
vides effective screening for trisomy 21 (Down syn-
drome), trisomy 18 (Edward syndrome), and trisomy 13 
(Patau syndrome) [1]. However, cffNIPT performance 
highly depends on the fetal fraction (FF), defined as the 
proportion of fetal-derived cell-free DNA in the total cell-
free DNA component found in maternal plasma. Thus, 
the FF must exceed 3–4% to provide a low false negative 
rate [2]. Several factors including body mass index (BMI) 
affect the FF. This is illustrated by a lower mean FF among 
women weighing 60 kg (12%) compared to women weigh-
ing 120 kg (6%) [3]. This association is explained by 
two factors: an increase in the concentration of cell-free 
maternal DNA and a decrease in the concentration of 
cffDNA [4]. The increase in the concentration of cell-free 
maternal DNA is due to enhanced necrosis and apoptosis 
of adipose tissue in obese pregnant women resulting in 
the leak of maternal DNA into the circulation [5]. The 
decrease in cffDNA concentration may be associated with 
an increased total blood volume in obese women result-
ing in the dilution of cffDNA [6]. Thus, increasing BMI 
and obesity are correlated with an increased risk of a 
failed cffNIPT result. Yared et al. [7] suggested a failure 
rate of 24.3% among obese women (BMI ≥30) compared 
with 3.7% in nonobese women. Consequently, there are 
limitations in the use of NIPT technology in the popula-
tion of obese pregnant women. 
Emerging technologies that source intact fetal cells 
from maternal blood have been proposed as superior al-
ternatives to cffNIPT. These technologies are called cell-
based noninvasive prenatal tests (cbNIPT). In conven-
tional cffNIPT, the DNA is fragmented and contami-
nated with maternal DNA making it difficult to detect 
small copy number variations in the fetal genome. Since 
fetal cells encompass the uncontaminated fetal genome, 
cbNIPT paves the way for progress in noninvasive prena-
tal testing [8]. Vestergaard et al. [9] previously demon-
strated that aneuploidies and even sub-chromosomal ab-
errations can be detected using this cbNIPT technology. 
However, the influence of BMI on the number of fetal 
cells and cbNIPT technology has not yet been explored. 
The objective of this study was to investigate the relation-
ship between maternal BMI and the number of fetal cells 
in venous blood samples. 
Methods
The study was approved by the Danish Research Ethics Com-
mittee (project ID: S-20070045). The data set consisted of 91 blood 
samples drawn sequentially as part of a larger validation study of 
the cbNIPT method conducted by ARCEDI Biotech ApS, a Danish 
biotech company that holds proprietary technology for the enrich-
ment and analysis of rare fetal extravillous trophoblast cells from 
pregnant women’s blood. Pregnant women at high risk of trisomy 
21 (> 1: 300 in the Danish combined first-trimester screening pro-
gram) who opted for invasive testing in the Central Region of Den-
mark were asked to participate. A total of 30 mL of blood was drawn 
from each woman. Blood processing, fetal cell enrichment as well 
as fetal cell staining and scanning was done as previously described 
[8, 10]. In short, red blood cells were lysed; the white blood cells 
were incubated with a fetal cell-specific antibody cocktail [8]. After 
incubation, the cells were applied to Miltenyi MS columns where 
fetal cells were enriched and stained using a cocktail of cytokeratin 
antibodies. Retained cells were eluted from the column and spread 
on glass slides. A fluorescence scanner (MetaSystems) located en-
riched and cytokeratin-stained fetal cells on the slides and final vi-
sual validation was performed by trained personnel. This method 
provides a high fetal cell specificity, which was previously validated 
and published by Kølvraa et al. in 2016 [8]. For the statistical anal-
ysis, the 91 subjects were subcategorized into four BMI weight 
classes according to WHO classification (< 18.5 = underweight; 
18.6–24.9 = normal; 25.0–29.9 = overweight; 30.0–39.0 = obese).
Results
The 91 pregnant women had a mean BMI of 23.9, 
which ranged between 17 and 38.7. The mean number of 
fetal cells per sample (30 mL of whole blood) was 12.6, 
with a range of 1–43 cells in one sample. The number of 
fetal cells, mean, median, range, and standard deviation 
in different groups are shown in Table 1. 
Fetal cell numbers in the four BMI groups are distrib-
uted as illustrated in the scatter plot (Fig. 1). The mean 
number of fetal cells per sample was 18.9 in the under-
weight group, 13.0 in the normal weight group, 10.1 in the 
overweight group, and 10.6 in the obese group. We did an 
analysis of variance (ANOVA), comparing the mean 
number of fetal cells in the four groups. Even though the 
decrease in the number of fetal cells with increased BMI 
was observed, the variance among the BMI groups was 
not statistically significant (p = 0.14). We also performed 
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the Kruskal-Wallis nonparametric test, and the associa-
tion of BMI with fetal cell numbers was still not signifi-
cant (p = 0.07).
Discussion
The present study on fetal cell numbers from 91 high-
risk pregnancies suggests that increasing maternal BMI 
tends to decrease the number of fetal cells in a venous 
blood sample, but not significantly. In particular, the un-
derweight and normal weight women present outliers 
with very high fetal cell numbers. No data was obtained 
from women who declined to participate. Consequently, 
our cohort may be affected by selection bias. However, we 
find this unlikely since the distribution of BMI in our data 
is similar to the distribution of BMI among Danish wom-
en in the age range of 16–44 years. In our study, 35.2% 
had a BMI ≥25 compared to 35.5% in the general popula-
tion according to The Danish National Health Survey 
20171 [11]. The lack of statistical significance of the cor-
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Table 1. The mean and median number of fetal cells in four BMI groups
Count, n Fetal cells Mean Median Range SD
Underweight 8 151 18.9 18.0 6–34 10.0
Normal 51 663 13.0 10.0 2–43 9.7
Overweight 22 224 10.2 8.0 1–37 8.9
Obese 10 106 10.6 9.5 1–25 8.0
SD, standard deviation.
Fig. 1. The scatter plot shows the distribu-
tion of fetal cells in 91 pregnant women. 
Each BMI subgroup is marked with a verti-
cal line. Extreme values of fetal cell num-
bers are more frequent in the underweight 
and normal weight group, and a decrease 
in the number of fetal cells trends with an 
increasing BMI. Md, median.
1 The Danish National Health Survey was funded by The Capital Region, 
Region Zealand, The South Denmark Region, The Central Denmark Region, 
The North Denmark Region, The Ministry of Health and the National Insti-
tute of Public Health, University of Southern Denmark.
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relation between fetal cell numbers and BMI might be due 
to the small sample size. There were only 8 and 10 samples 
in the underweight and obese groups, respectively. Hav-
ing more samples in these two groups could lead to an 
increase in the statistical power of the test. 
Importantly, however, none of the samples, not even 
in the obese group, came out with 0 fetal cells, which oth-
erwise could impact cbNIPT since at least one fetal cell is 
needed for downstream genetic analysis. Kølvraa et al. [8] 
demonstrated, that cbNIPT can be performed on as few 
as one fetal cell using whole genome amplification, array 
comparative genomic hybridization, and next-genera-
tion sequencing. Furthermore, the study by Vestergaard 
et al. [9] demonstrated that these fetal trophoblast cells 
could be used successfully in cbNIPT to detect chromo-
somal and sub-chromosomal abnormalities. When seen 
through the light of these previous results, the current 
data suggests that cbNIPT should not be hampered by an 
increased BMI because every pregnancy, irrespective of 
the BMI, has rendered fetal cells for downstream genetic 
analysis. The current data is from high-risk pregnancies. 
We have previously investigated if the number of fetal 
cells is different between high-risk and low-risk pregnan-
cies and found that the mean and distribution of fetal cells 
is similar in two groups (data not published). This also 
implies that the current data on the BMI and fetal cells 
from high-risk pregnancies could very well be transfer-
able to the low-risk population.
ARCEDI Biotech is currently conducting a study on 
high-risk pregnancies that compares the results from 
cffNIPT, cbNIPT, and chorionic villi samples to validate 
the performance of cbNIPT. 
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